Collaboration between Pfizer and Evotec

Licence and collaboration agreement in tissue fibrosis

10-Sep-2015 - Germany

Evotec AG announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.

Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer will explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform whereas Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.

Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances